Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13 mars 2020 uppdaterad av: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Studieöversikt

Status

Okänd

Detaljerad beskrivning

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Studietyp

Interventionell

Inskrivning (Förväntat)

50

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Clermont-Ferrand, Frankrike, 63000
        • CHU de Clermont-Ferrand

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

12 år till 16 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Inget ingripande: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
cardiac ectopic fat deposits
Tidsram: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Tidsram: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Tidsram: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Tidsram: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Tidsram: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Tidsram: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Tidsram: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Tidsram: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Tidsram: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Tidsram: Day 0
left myocardial regional function (MRI)
Day 0

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
macrovascularisation
Tidsram: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Tidsram: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Tidsram: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Tidsram: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Tidsram: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Tidsram: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Tidsram: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Tidsram: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Tidsram: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Tidsram: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Tidsram: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Tidsram: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Tidsram: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Tidsram: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Tidsram: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Tidsram: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Tidsram: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Tidsram: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Tidsram: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Tidsram: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Tidsram: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Tidsram: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Tidsram: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Tidsram: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Tidsram: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Tidsram: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Tidsram: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Tidsram: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Tidsram: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Tidsram: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Tidsram: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Tidsram: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Tidsram: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Tidsram: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Tidsram: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Tidsram: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Tidsram: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Tidsram: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Tidsram: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Tidsram: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Tidsram: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Tidsram: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Tidsram: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Tidsram: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Tidsram: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Tidsram: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Tidsram: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Tidsram: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Tidsram: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Tidsram: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Tidsram: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Tidsram: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Tidsram: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Tidsram: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Tidsram: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Tidsram: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Tidsram: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Tidsram: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Tidsram: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Tidsram: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Tidsram: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Tidsram: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Tidsram: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Tidsram: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Tidsram: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Tidsram: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Tidsram: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Tidsram: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Tidsram: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Tidsram: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Tidsram: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Tidsram: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Tidsram: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Tidsram: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Tidsram: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Tidsram: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Tidsram: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Tidsram: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Tidsram: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Tidsram: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Tidsram: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Tidsram: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Tidsram: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Tidsram: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Tidsram: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Tidsram: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Tidsram: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Tidsram: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Tidsram: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Tidsram: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Tidsram: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Tidsram: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Tidsram: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Tidsram: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Tidsram: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Tidsram: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Tidsram: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Tidsram: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Tidsram: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Tidsram: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Tidsram: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Tidsram: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Tidsram: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Tidsram: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Tidsram: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Tidsram: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Tidsram: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Tidsram: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Tidsram: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Tidsram: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Tidsram: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Tidsram: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Tidsram: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Tidsram: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Tidsram: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Tidsram: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Tidsram: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Tidsram: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Tidsram: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Tidsram: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Tidsram: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Tidsram: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Tidsram: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Tidsram: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Tidsram: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Tidsram: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Tidsram: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Tidsram: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Tidsram: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Tidsram: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Tidsram: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Tidsram: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Tidsram: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Tidsram: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Tidsram: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Tidsram: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Tidsram: Day 0
measure of weight in kilograms
Day 0
weight
Tidsram: Month 3
measure of weight in kilograms
Month 3
waist circumference
Tidsram: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Tidsram: Month 3
measure of waist circumference in centimetres
Month 3

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Förväntat)

1 september 2020

Primärt slutförande (Förväntat)

1 juni 2021

Avslutad studie (Förväntat)

1 juni 2021

Studieregistreringsdatum

Först inskickad

10 februari 2020

Först inskickad som uppfyllde QC-kriterierna

13 mars 2020

Första postat (Faktisk)

17 mars 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 mars 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 mars 2020

Senast verifierad

1 februari 2020

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Annan identifierare: ANSM)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

Obeslutsam

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera